NasdaqGS:INVAPharmaceuticals
Is Innoviva (INVA) Undervalued After Nortiva Bio Launch And XACDURO Deal?
Innoviva event recap and why it matters for shareholders
Innoviva (INVA) has attracted fresh attention after launching Nortiva Bio, a clinical-stage subsidiary built around the LYNX long-acting oral drug platform, alongside a new XACDURO distribution and licensing agreement with Dr. Reddy's Laboratories.
See our latest analysis for Innoviva.
Against this backdrop, Innoviva’s share price return of 18.62% year to date and 10.04% 1 month share price return point to building momentum, while the...